Skip to main content

Advertisement

Log in

The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer

  • Original Article
  • Published:
International Journal of Colorectal Disease Aims and scope Submit manuscript

Abstract

Background

Low serum albumin was found as a predictor of long-term mortality in colorectal cancer (CRC) patients. Our aim was to evaluate the value of the pretreatment albumin/globulin ratio (AGR) to predict the long-term mortality in CRC patients.

Methods

Patients were included if they had comprehensive metabolic panel (CMP) before treatment (surgery or chemotherapy). The albumin/globulin ratio, routinely reported in CMP, is calculated [AGR = Albumin/(Total protein − Albumin)]. Patients were divided into three equal tertiles according to their pretreatment AGR. The primary outcome was cancer-related mortality, which was obtained from our cancer registry database.

Results

A total of 534 consecutive CRC patients had pretreatment CMP. The 1st AGR tertile had a significant higher 4-year mortality compared to the second and third AGR tertiles (42 vs. 19 and 7 %, p < 0.0001 according to Fisher’s exact two-tailed test). In the multivariate model, AGR remained an independent predictor of survival with 75 % decrease in mortality among the highest AGR tertile in comparison to the lowest AGR tertile, p < 0.0001. In the subset of 234 patients with normal serum albumin (albumin of >3.5 g/dl), serum AGR continues to be an independent predictor of cancer-related mortality with an adjusted hazard ratio of the third tertile compared to the first tertile equal to 0.05 (95 % confidence interval 0.01–0.33, p = 0.002).

Conclusion

Low AGR was a strong independent predictor of long-term cancer-specific survival among colorectal cancer patients. Additionally, among the patients with normal albumin (>3.5 g/dl), patients with lower globulins but higher albumin and AGR levels had better survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. American Cancer Society (2011) Colorectal cancer facts & figures 2011–2013. American Cancer Society, Atlanta

    Google Scholar 

  2. Betge J, Pollheimer MJ, Lindtner RA et al (2012) Intramural and extramural vascular invasion in colorectal cancer: prognostic significance and quality of pathology reporting. Cancer 118(3):628–638

    Article  PubMed  Google Scholar 

  3. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK (2010) Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol 28(2):264–271

    Article  PubMed  Google Scholar 

  4. Huh JW, Kim HR, Kim YJ (2010) Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. J Gastrointest Surg 14(7):1074–1080

    Article  PubMed  Google Scholar 

  5. Swanson RS, Compton CC, Stewart AK, Bland KI (2003) The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10(1):65–71

    Article  PubMed  Google Scholar 

  6. Wohlke M, Schiffmann L, Prall F (2011) Aggressive colorectal carcinoma phenotypes of invasion can be assessed reproducibly and effectively predict poor survival: interobserver study and multivariate survival analysis of a prospectively collected series of 299 patients after potentially curative resections with long-term follow-up. Histopathology 59(5):857–866

    Article  PubMed  Google Scholar 

  7. Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M (2011) Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med 2(1):95–101

    PubMed  Google Scholar 

  8. Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol 6(1):149–163

    Article  PubMed  CAS  Google Scholar 

  9. Inoue Y, Iwata T, Okugawa Y et al (2013) Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer. Oncology 84(2):100–107

    Article  PubMed  CAS  Google Scholar 

  10. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 30(7):1073–1081

    Article  PubMed  CAS  Google Scholar 

  11. McPherson R, Pincus MR (2011) Henry’s clinical diagnosis and management by laboratory methods, 22nd edn. Saunders, Philadelphia

    Google Scholar 

  12. Gabay C, Kushner I (1999) Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340(6):448–454

    Article  PubMed  CAS  Google Scholar 

  13. McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer 39(2):210–213

    Article  PubMed  CAS  Google Scholar 

  14. Fearon KC, Falconer JS, Slater C, McMillan DC, Ross JA, Preston T (1998) Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response. Ann Surg 227(2):249–254

    Article  PubMed  CAS  Google Scholar 

  15. Andersson C, Lonnroth C, Moldawer LL, Ternell M, Lundholm K (1990) Increased degradation of albumin in cancer is not due to conformational or chemical modifications in the albumin molecule. J Surg Res 49(1):23–29

    Article  PubMed  CAS  Google Scholar 

  16. Lai CC, You JF, Yeh CY et al (2011) Low preoperative serum albumin in colon cancer: a risk factor for poor outcome. Int J Color Dis 26(4):473–481

    Article  Google Scholar 

  17. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007) Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Color Dis 22(8):881–886

    Article  Google Scholar 

  18. Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69

    Article  PubMed  Google Scholar 

  19. Cengiz O, Kocer B, Surmeli S, Santicky MJ, Soran A (2006) Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit 12(6):CR240–CR247

    PubMed  CAS  Google Scholar 

  20. Dixon MR, Haukoos JS, Udani SM et al (2003) Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Arch Surg 138(9):962–966

    Article  PubMed  Google Scholar 

  21. Heys SD, Walker LG, Deehan DJ, Eremin OE (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43(3):163–168

    PubMed  CAS  Google Scholar 

  22. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K (2007) Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg 246(6):1047–1051

    Article  PubMed  Google Scholar 

  23. Kaysen GA (2001) The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol: JASN 12(7):1549–1557

    PubMed  CAS  Google Scholar 

  24. Kaysen GA (2003) Serum albumin concentration in dialysis patients: why does it remain resistant to therapy? Kidney Int Suppl 87:S92–S98

    Article  PubMed  Google Scholar 

  25. Sonnenschein C, Soto AM, Michaelson CL (1996) Human serum albumin shares the properties of estrocolyone-I, the inhibitor of the proliferation of estrogen-target cells. J Steroid Biochem Mol Biol 59(2):147–154

    Article  PubMed  CAS  Google Scholar 

  26. Laursen I, Briand P, Lykkesfeldt AE (1990) Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7. Anticancer Res 10(2A):343–351

    PubMed  CAS  Google Scholar 

  27. Cohen MH, Makuch R, Johnston-Early A et al (1981) Laboratory parameters as an alternative to performance status in prognostic stratification of patients with small cell lung cancer. Cancer Treat Rep 65(3–4):187–195

    PubMed  CAS  Google Scholar 

  28. Codina Cazador A, Salva Lacombe JA, Fernandez-Llamazares Rodriguez J, Ruiz Feliu B, Codina Barreras A, Moreno Aguado V (1989) Immunoglobulins and the complement system in colorectal cancer. Rev Esp Enferm Apar Dig 75(2):143–148

    PubMed  CAS  Google Scholar 

  29. Oner F, Savas I, Numanoglu N (2004) Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 52(1):19–23

    PubMed  Google Scholar 

  30. Shimada H, Nabeya Y, Okazumi S et al (2003) Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83(4):248–252

    Article  PubMed  Google Scholar 

  31. Gerhardt T, Milz S, Schepke M et al (2006) C-reactive protein is a prognostic indicator in patients with perihilar cholangiocarcinoma. World J Gastroenterol 12(34):5495–5500

    PubMed  CAS  Google Scholar 

  32. Canna K, McArdle PA, McMillan DC et al (2005) The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer 92(4):651–654

    Article  PubMed  CAS  Google Scholar 

  33. Osman W, Okada Y, Kamatani Y, Kubo M, Matsuda K, Nakamura Y (2012) Association of common variants in TNFRSF13B, TNFSF13, and ANXA3 with serum levels of non-albumin protein and immunoglobulin isotypes in Japanese. PLoS One 7(4):e32683

    Article  PubMed  CAS  Google Scholar 

  34. Al-Joudi FS (2005) Prognostic value of an index for serum globulin compensation in colon and breast cancers. Singap Med J 46(12):710–713

    CAS  Google Scholar 

  35. Hong KW, Jin HS, Song D, Kwak HK, Soo Kim S, Kim Y (2013) Genome-wide association study of serum albumin:globulin ratio in Korean populations. J Hum Genet 58(3):174–177

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors report no potential conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Basem Azab.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Azab, B., Kedia, S., Shah, N. et al. The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer. Int J Colorectal Dis 28, 1629–1636 (2013). https://doi.org/10.1007/s00384-013-1748-z

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00384-013-1748-z

Keywords

Navigation